CNTB Connect BiopharmaWatchlist
About Connect Biopharma Company
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.
Will Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after l
Simcere Pharma, Connect Biopharma Enter Into Agreement For Autoimmune Drug Rademikibart
Why Is Skin Disease-Focused Connect Biopharma Stock Lower Today?
Connect Biopharma Holdings Limited (NASDAQ:CNTB) released topline results from Stage 2 (maintenance period) of its China pivotal trial evaluating rademikibart's (formerly known as CBP-201) efficacy an
2. Wheeler Real Estate IT ( $Wheeler Real Estate Investment Trust Inc(WHLR.US)$ ) shares are soaring over 47% as it also sees strong early morning trading on Wednesday.
3. Heart Test Laboratories ( $Heart Test Laboratories(HSCS.US)$ ) stock is surging close to 29% after closing a licensing agreement.
4. Getaround ( $Getaround(GETR.US)$ ) shares are gain...